News of Note—Clementia IPO; Eloxx series C; Collidion-Plex stake

Investment is the name of the game in today's news of note.

> Following on from a spate of biotech public offerings in recent months, ultrarare bone disease biotech Clementia has priced its IPO at the high end at $15 a pop, bringing in a chunky $120 million. Insiders bought about a quarter of the shares. The Canadian biotech plans to use the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Release

> Eloxx Pharmaceuticals has gained an additional $8 million investment by LSP, a healthcare investor, boosting its series C to $38 million. The funds will be put toward its work on genetic diseases caused by nonsense mutations. Statement

> And it's money news galore as Collidion and Plex Pharmaceuticals have penned a new deal that sees Collidion get its hands on an 80% equity stake in Plex in exchange for an “undisclosed amount of cash and contributing a novel drug asset under development.” The pact also sees Collidion give “management and operational support” as Plex works on meds for Parkinson's disease, glioblastoma and cataracts. Release

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.